Home Cart Sign in  
Chemical Structure| 1783-84-2 Chemical Structure| 1783-84-2

Structure of Dihomo-γ-linolenic acid
CAS No.: 1783-84-2

Chemical Structure| 1783-84-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid with anti-inflammatory and antiproliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in apolipoprotein E-deficient mouse models.

Synonyms: DGLA; all-cis-8,11,14-Eicosatrienoic acid; Diroleuton

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dihomo-γ-linolenic acid

CAS No. :1783-84-2
Formula : C20H34O2
M.W : 306.48
SMILES Code : CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(O)=O
Synonyms :
DGLA; all-cis-8,11,14-Eicosatrienoic acid; Diroleuton
MDL No. :MFCD00065721

Safety of Dihomo-γ-linolenic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H227
Precautionary Statements:P501-P210-P280-P370+P378-P403+P235

Related Pathways of Dihomo-γ-linolenic acid

pyroptosis

Isoform Comparison

Biological Activity

Description
Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid noted for its anti-inflammatory and anti-proliferative properties. It is effective in reducing atherosclerosis in apolipoprotein E-deficient mice, a commonly used model for studying this condition[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 cells 100 µM 48 h Inhibited cell growth and promoted the formation of 8-HOA Free Radic Biol Med. 2016 Jul;96:67-77
HCA-7 colony 29 cells 100 µM 48 h Inhibited cell growth and promoted the formation of 8-HOA Free Radic Biol Med. 2016 Jul;96:67-77
SKBR3 and MDAMB231 breast cancer cell lines 20 μM 12 h DGLA ethyl ester reduced the radioactivity incorporated into the fatty acid fractions by 40 to 50% and FAS activities by 20–40%. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15757-62
3T3-L1 preadipocytes 20 μM 24 h DGLA treatment reduced the [13C]-acetate incorporation into [13C]-palmitate by 51%. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15757-62
BxPC-3 cells 100 μM 48 h To evaluate the inhibitory effects of DGLA on BxPC-3 cell growth and its synergistic effects with chemotherapy drugs. Results showed that DGLA treatment significantly inhibited colony formation in D5D-knockdown BxPC-3 cells (survival fraction ~70.6%) and enhanced the cytotoxicity of chemotherapy drugs such as gemcitabine. Free Radic Biol Med. 2016 Aug;97:342-350
BxPC-3 cells 100 µM 48 h Promoted 8-HOA formation and inhibited cancer cell growth Redox Biol. 2019 Jan;20:236-246
Glutamatergic neurons 100 μM From L4 stage DGLA caused cell loss in glutamatergic neurons at a later stage ACS Cent Sci. 2023 Mar 16;9(5):870-882
Dopaminergic neurons 100 μM From L4 stage DGLA significantly induced degeneration in dopaminergic neurons ACS Cent Sci. 2023 Mar 16;9(5):870-882

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous xenograft tumor model Oral gavage 8 mg/mouse Twice a week for 4 weeks Inhibited tumor growth and metastatic potential Redox Biol. 2019 Jan;20:236-246

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.26mL

0.65mL

0.33mL

16.31mL

3.26mL

1.63mL

32.63mL

6.53mL

3.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories